Orthocell Appoints UK Distributor for Remplir
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell Ltd has appointed LEDA Orthopaedics as the exclusive distributor for Remplir in the UK, a key step in its market strategy for the UK and EU valued at a significant amount. This appointment follows a regulatory submission to the British Standards Institution for approval to distribute Remplir, with a decision expected in the near future. The partnership aims to prepare for a rapid commercial launch of Remplir, leveraging LEDA's established relationships with surgeons and experience in orthopaedic technologies. Orthocell remains well funded, with substantial cash reserves to support its global distribution strategy and regulatory programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Appendix 4D & Half-Year Financial Report
- Orthocell Receives $3.0m R&D Tax Refund
- US Market and Operational Update
- Quarterly Activity Report & Appendix 4C
- Orthocell Posts Seventh Straight Record Revenue Quarter
Later from Orthocell
- Remplir Used in 23 Surgeries in Ukrainian soldiers
- OCC Secures Access to 221 U.S. Military Medical Centres
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
- First Surgical Use of Remplir in US Department of Defense
- Q3 FY26 Investor Presentation
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell